3rd CRISPR 2.0 Summit 2022

Temi della conferenza
Recognised with a Nobel Prize in 2020, CRISPR has opened the floodgates for a new era of gene editing therapies, promising to transform genetic disease treatments. With a well-established early field of genomics research, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit, including Cas nucleases, base and prime editing technologies, and innovative delivery platforms.

Professional congress organizer (PCO)
Hanson Wade

Annotazioni
Brochure: https://go.evvnt.com/1278515-2?pid=4832

Speakers: Aditya Raguram, PhD Student David Liu Lab, Harvard University, Alexandra Crawley, Co-Founder and Senior Scientist, LifeEDIT, Amy Simon, Chief Medical Officer, Beam Therapeutics, and more.

https://go.evvnt.com/1278515-3?pid=4832

Ms. Min Ratcliffe